- Home
- AHH vs DNTH Comparison
AHH vs DNTH Comparison
Compare AHH & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHH
- DNTH
- Stock Information
- Founded
- AHH 1979
- DNTH 2015
- Country
- AHH United States
- DNTH United States
- Employees
- AHH N/A
- DNTH N/A
- Industry
- AHH Real Estate
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- AHH Finance
- DNTH Health Care
- Exchange
- AHH Nasdaq
- DNTH Nasdaq
- Market Cap
- AHH 821.2M
- DNTH 711.2M
- IPO Year
- AHH 2013
- DNTH N/A
- Fundamental
- Price
- AHH $9.95
- DNTH $21.66
- Analyst Decision
- AHH Buy
- DNTH Strong Buy
- Analyst Count
- AHH 2
- DNTH 9
- Target Price
- AHH $11.88
- DNTH $46.43
- AVG Volume (30 Days)
- AHH 1.0M
- DNTH 285.9K
- Earning Date
- AHH 02-20-2025
- DNTH 11-07-2024
- Dividend Yield
- AHH 8.24%
- DNTH N/A
- EPS Growth
- AHH N/A
- DNTH N/A
- EPS
- AHH N/A
- DNTH N/A
- Revenue
- AHH $756,903,000.00
- DNTH $5,366,000.00
- Revenue This Year
- AHH N/A
- DNTH $100.14
- Revenue Next Year
- AHH $5.79
- DNTH N/A
- P/E Ratio
- AHH N/A
- DNTH N/A
- Revenue Growth
- AHH 19.33
- DNTH 51.41
- 52 Week Low
- AHH $9.26
- DNTH $14.82
- 52 Week High
- AHH $12.46
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- AHH 44.90
- DNTH 45.12
- Support Level
- AHH $9.26
- DNTH $18.72
- Resistance Level
- AHH $10.27
- DNTH $28.65
- Average True Range (ATR)
- AHH 0.23
- DNTH 2.31
- MACD
- AHH 0.02
- DNTH -0.33
- Stochastic Oscillator
- AHH 68.32
- DNTH 32.14
About AHH Armada Hoffler Properties Inc.
Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. They lease our properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting and real estate services. It generates maximum revenue from the general contracting and real estate services segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.